Hefei Afana Biotechnology Co., Ltd
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Hefei Afana Biotechnology Co., Ltd - overview
Established
2021
Location
Hefei, Anhui, China
Primary Industry
Biotechnology
About
Based in Hefei, China, and founded in 2021, Hefei Afana Biotechnology Co. , Ltd operates as an mRNA drug developer. As of 2022, the company completed a round of financing. The company's founder Yucai Wang has focused on the research of nanocarrier and nucleic acid delivery technology for more than 15 years.
The company is specializing in mRNA sequence optimization and delivery system in the field of covid-19 mutant vaccine development. The mRNA technology can be applied in the preventive vaccine, tumor immunotherapy, protein replacement therapy, and regenerative therapy.
Current Investors
Zhongtou Zhongcai Capital, Guoyuan Fund, Green Harbor Investment
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Pharmaceutical Research & Development
Company Stage
Late Stage
Total Amount Raised
Subscriber access only
Hefei Afana Biotechnology Co., Ltd - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.